Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,576.76
(
-0.06%
)
US TECH 100
23,422.80
(
-0.41%
)
Dow Jones
46,278.62
(
0.15%
)
Brent Oil
100.31
(
3.63%
)
Bitcoin
69,500.00
(
-1.97%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 242413

Thursday, 02/16/2023 10:12:14 AM

Thursday, February 16, 2023 10:12:14 AM

Post# of 257275
PFE’s zavegepant phase-3 published_in The Lancet Neurology

https://www.businesswire.com/news/home/20230216005209/en

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2822%2900517-8/fulltext

Zavegepant, which PFE picked up in the 2022 BHVN acquisition, is a CGRP for acute migraine treatment that is administered intranasally.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today